Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate plus hydroxyurea versus placebo plus hydroxyurea in sickle cell disease
RBR-57qbjvPhase 2Not yet recruiting
- Sponsor
- Centro Infantil Boldrini
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in sickle cell disease (SCD) comparing methotrexate + hydroxyurea with Control: placebo + hydroxyurea (2 arms). Planned start Aug 2018; status: not yet recruiting.
02
Drugs
methotrexate
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on RBR-57qbjv.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-57qbjv.